EGFR and non-small cell lung carcinoma: Overall, clonally expanded Vβ5-6Jβ2-1, Vβ20-1Jβ2-1, and Vβ24-1Jβ2-1 might be beneficial for resectable early-stage patients with NSCLC choosing TKI therapy as adjuvant treatment, while clonally expanded Vβ29-1Jβ2-7 may be an indicator for patients with an EGFR mutation choosing chemotherapy as adjuvant treatment.